Presented by: Dr. Kirsten Heiss - Scientist Biomarker Discovery, PEPperPRINT GmbH
Date: June 2, 2021
In a joint study with the Institute of Virolgy at the Charité, we analyzed COVID-19 patient sera using peptide microarrays covering the entire SARS-CoV-2 proteome and identified potential epitope signatures with a prognostic value for disease outcome. In this webinar, Dr. Kirsten Heiss takes us through the study and explains how this approach can be used to investigate potential epitope biomarkers for other emerging diseases.
Download presentation slides [pdf]
- Discover a new approach to characterization and profiling of antibody responses against SARS-CoV-2.
- Get to know the benefits of using peptide microarrays for high throughput screening of serological samples against multiple antigens.
- How peptide microarrays can be used as a rapid-response research tool for immunogenic epitope detection of any pathogen.
About the presenter
Dr. Kirsten Heiss received her PhD in infectious diseases from the Ruprecht-Karls-University Heidelberg in 2006 working on the malaria-causing agent Plasmodium. Further Postdoc studies at the Institute of Immunology at University Hospital Hamburg-Eppendorf enabled her to combine infections with immunology. Back in Heidelberg in 2009, working as scientist at the Center for Infectious Diseases at the University Hospital Heidelberg, her research interests focused on vaccine development and the identification of novel targets for intervention strategies against malaria. In 2018, she joined the R&D unit of PEPperPRINT GmbH and is responsible for the discovery of novel antibody-mediated biomarkers in the field of autoimmune und infectious diseases.